Cas9 Stable Cell Line - H9c2(2-1)

The H9c2(2-1) cell line is a subclone derived from the original H9c2 rat cardiac myoblast cell line, which was initially isolated from the embryonic heart tissue of BD1X rats. These cells possess skeletal muscle-like characteristics and can differentiate into a cardiomyocyte-like phenotype under low serum conditions, making them an important model for cardiovascular research. The Cas9 Stable Cell Line - H9c2(2-1) is a genetically engineered variant in which the CRISPR-associated protein 9 (Cas9) endonuclease is stably integrated into the H9c2(2-1) genome. This modification ensures stable, high-level expression of Cas9 without the need for repeated transfections, thus providing a powerful platform for efficient and precise genome editing. This cell line has undergone rigorous validation to confirm Cas9 function, genetic stability, and maintenance of parental cell characteristics.

The Cas9 Stable Cell Line - H9c2(2-1) has broad application prospects in molecular biology and drug development. In cardiovascular disease modeling, researchers use this cell line to knock out or knock in genes associated with cardiac hypertrophy, arrhythmias, or metabolic dysfunction, thereby facilitating research into the pathway mechanisms of heart failure. For example, targeting genes that disrupt ion channels (such as KCNH2) can be used to study electrophysiological abnormalities. Stable Cas9 expression also accelerates high-throughput screening of novel drug targets. By introducing guide RNA libraries, scientists can perform genome-wide CRISPR screening to identify genes that affect the survival of cardiomyocytes under hypoxia or oxidative stress. In toxicology, it can help assess the cardiotoxic effects of drugs by editing genes involved in drug metabolism.